With Two BCMA-Targeting Myeloma Treatments, Which Should Be First Choice?
Experts Weigh In On Positioning BMS/Bluebird’s Abecma And GSK’s Blenrep
Market Snapshot: GSK's Blenrep and BMS's Abecma are the first of many drugs for the late-line setting. In many cases, the CAR-T may be the first choice, but some patients are unable to handle it or risk progressing while awaiting treatment.
You may also be interested in...
Amgen’s $3.7bn ChemoCentryx Buy May Help Offset Growing Pains
Amgen is acquiring a pipeline-in-a-pill with ChemoCentryx’s Tavneos, currently approved for ANCA-associated vasculitis, at a time when the company’s existing portfolio is struggling to maintain sales growth.
GSK Grows Immuno-Oncology Credentials With New Dostarlimab Indication
GlaxoSmithKline’s checkpoint inhibitor Jemperli has gained a second indication in the US, for the treatment of mismatch repair-deficient solid tumors, affirming the company’s drive to develop a new portfolio of cancer therapies.
BCMA Drug Prices For Multiple Myeloma Don't Match Their Benefit, ICER Concludes
Despite the net health benefits of Abecma, the price is too high, while Blenrep has low long-term value for the cost, according to ICER's benchmarks.